CHANGE IN CONTROL AND SEVERANCE AGREEMENTRelease Agreement • March 2nd, 2020 • Fibrogen Inc • Pharmaceutical preparations • California
This Change in Control and Severance Agreement (this “Agreement”) is dated as of ____________ (the “Effective Date”), by and between [______________] (“Executive”) and FibroGen, Inc., a Delaware corporation (the “Company”). This Agreement is intended to provide Executive with certain benefits described herein upon the occurrence of specific events.
COMMERCIAL SUPPLY AGREEMENT (Roxadustat)Commercial Supply Agreement • March 2nd, 2020 • Fibrogen Inc • Pharmaceutical preparations
This Commercial Supply Agreement (the “Agreement”) is effective as of January 1, 2020 (the “Effective Date”), by and between FibroGen, Inc., a Delaware corporation with offices located at 409 Illinois Street, San Francisco, California 94158, and its Affiliates (collectively, “FibroGen”), and Catalent Pharma Solutions, LLC, a Delaware limited liability corporation having an address at 14 Schoolhouse Road, Somerset, New Jersey 08873 (“Catalent”). Catalent and each of its Affiliates shall collectively be referred to herein as “Catalent”. FibroGen and Catalent may be referred to individually as a “Party”, and collectively as the “Parties”.
